AzTrials
AzTrials

MyopiaPhase 2NCT07863713

Early Intervention for High Risk Premyopic Children

A Phase 2 study testing 0.025% atropine eye drops and DIMS TED in people with Myopia, run by National Yang Ming Chiao Tung University Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention… Read more about this study

Who is it for?
Ages 5 to 6 yearsHealthy volunteers can take part
Conditions the study is for
Myopia
What is being tested?
0.025% atropine eye drops and DIMS TED
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
240 participants
Where
No sites listed yet
Study dates
24 Oct 2026to 24 Oct 2033
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 6 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Age at enrollment: 5-6 years old (the senior grade of kindergarten)
  • Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): < +1.00 D and > -0.50 D
  • Astigmatism: 1.5 D or less in both eyes
  • Anisometropia: 1.50 D or less
  • Monocular uncorrected visual acuity: 6/7.5 or better in both eyes
  • Either of the parents with moderate myopia
  • Acceptance of random group allocation
  • Submission of complete informed consent.

Who cannot join

  • Strabismus or any ocular motility disorder
  • Any ophthalmic and systemic disorders that might affect visual functions or refractive development
  • Previous treatment of atropine or other myopia control intervention

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Early Intervention for High Risk Premyopic Children: A Comparison Study of Defocus Integrated Multiple Segments Triple Enhanced Design Spectacle Lenses, 0.025% Atropine and Usual Care for Myopia Prevention

The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.

Read the detailed description

With the increasing popularity of screen-based digital devices in the post-pandemic era, childhood myopia prevention and control has become a growing global challenge. Although the protective effect of increased outdoor time has been well established, the optimal strategy for preventing or delaying the onset of childhood myopia remains to be determined, particularly among pre-myopic children around the age of school entry. A substantial increase in myopia prevalence has been reported before and after entry into elementary school, and children with early-onset myopia are at increased risk of rapid progression and subsequent development of high myopia later in life.

Recent evidence suggests that low-concentration atropine eye drops may reduce the incidence of childhood myopia. However, photophobia and other dose-related adverse effects associated with higher concentrations of atropine may interfere with daytime visual activities and potentially reduce children's willingness to engage in outdoor activities. In addition, evidence regarding optical interventions for the prevention of myopia onset remains limited.

These unmet clinical needs motivate us to propose a randomized controlled trial evaluating optical and pharmacological approaches for myopia prevention using Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) spectacle lenses and 0.025% atropine eye drops, respectively, in pre-myopic preschool children aged 5-6 years.

In this proposed study, we plan to recruit a total of 240 eligible participants identified as pre-myopic and asymptomatic through a population-based eye care program in Yilan County. Eligible participants will be randomly assigned to three groups: the DIMS TED spectacle lens group (n=80), the 0.025% atropine group (n=80), and the usual-care group (n=80).

Because environmental and near-work demands are generally lower during preschool than after entry into elementary school, children assigned to the DIMS TED group will be instructed to wear the spectacles using a stepwise strategy: primarily at home and during near-work activities during the preschool stage, followed by full-time wear after entering elementary school.

Cycloplegic spherical equivalent (SE) refraction and axial length will be measured every 6 months during the 7-year follow-up period. The primary outcome will be the change in mean cycloplegic SE over the study period among the three groups. Secondary outcomes will include the cumulative incidence of myopia, the cumulative proportion of participants exhibiting a fast myopic shift in SE, and changes in mean axial length over the study period.

This proposed project may provide further evidence regarding early optical and pharmacological intervention strategies for myopia prevention and may support the development of an eye-care model emphasizing early identification and intervention for pre-myopic preschool children before or around the time of elementary school entry.

Conditions
Myopia
Being tested
0.025% atropine eye drops, DIMS TED
Keywords
myopia, DIMS TED, Atropine, Outdoor activities
Medical subject headings
Myopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 0.025% atropine eye dropsDrug

    Daily instillation of 0.025% atropine

  • DIMS TEDDevice

    Stepwise wearing of DIMS TED

Study groups in NCT07863713
Study groupRoleWhat they receive
DIMS TEDActive comparatorStepwise wearing of DIMS TED
Receives: Device: DIMS TED
0.025% AtropineActive comparatorDaily administration of 0.025% Atropine
Receives: Drug: 0.025% atropine eye drops
Normal activitiesNo interventionNormal promotion of outdoor activities

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Myopic shift of spherical equivalent refraction

    The change of mean cycloplegic spherical equivalent refraction over 7 years

    Measured: 7 years

Secondary outcomes (4)
  1. Axial length elongation

    The change of mean axial length over 7 years

    Measured: 7 years

  2. Incidence of myopia

    the cumulative percentage of incident myopia

    Measured: 7 years

  3. Fast myopic shift of spherical equivalent refraction

    the cumulative percentage of fast myopic shift of spherical equivalent refraction

    Measured: 7 years

  4. Subfoveal choroidal thickness

    the vertical distance from the outer edge of the retinal pigment epithelium (or Bruch's membrane) to the inner surface of the sclera (the chorioscleral border) directly beneath the fovea

    Measured: 7 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2026
  2. Study start24 Oct 2026 (estimated)
  3. Primary completion24 Oct 2033 (estimated)
  4. Study completion24 Oct 2033 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
240 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07863713
Sponsor's protocol ID
Premyopia PQR study
Status last verified
Oct 2026
First submitted
2 Oct 2026
Last updated
7 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in